UK-based BiVictriX Therapeutics Plc has appointed Glyn Baker as chief financial officer. BiVictriX is developing cancer therapies that target antigen co-expression fingerprints on tumour cells. Mr Baker joins the company from a Cambridge, UK start-up working in neurology. Prior to this, he was finance director at Inflazome Ltd, developer of inhibitors of innate immune system receptors for the treatment of inflammatory diseases. Inflazome was acquired by Roche in 2020.
BiVictriZ Therapeutics announced the appointment on 6 January 2022.
Copyright 2022 Evernow Publishing Ltd